IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kennedy, M. J.
Right arrow Articles by Curtiss, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, M. J.
Right arrow Articles by Curtiss, R., III

Infection and Immunity, September 1999, p. 4628-4636, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Attenuation and Immunogenicity of Delta cya Delta crp Derivatives of Salmonella choleraesuis in Pigs

Michael J. Kennedy,1,* Robert J. Yancey Jr.,1,dagger Margaret S. Sanchez,1 Robert A. Rzepkowski,1 Sandra M. Kelly,2 and Roy Curtiss III3

Animal Health Discovery Research, Veterinary Infectious Diseases Section, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 490011; MEGAN Health, St. Louis, Missouri 631102; and Washington University, St. Louis, Missouri 631303

Received 4 February 1999/Returned for modification 16 April 1999/Accepted 14 June 1999

Six different isogenic Delta cya Delta crp derivatives of a strain of Salmonella choleraesuis var. kunzendorf-chi 3246 virulent for pigs were constructed by transposon-mediated deletion mutagenesis. These strains were evaluated for virulence and ability to elicit a protective immune response in young weaned pigs after oral administration and were compared to a commercially available vaccine which lacks the 50-kb virulence plasmid (vpl-). These derivatives were Delta cya Delta crp vpl+, Delta cya Delta crp vpl-, Delta cya Delta (crp-cdt) vpl+, Delta cya Delta (crp-cdt) vpl-, Delta cya Delta crp pmi-3834 vpl+, and Delta cya Delta (crp-cdt) pmi-3834. In experiments to evaluate safety, no significant adverse effects of any of the vaccine constructs were observed, except that two of the strains which carried the virulence plasmid (vpl+) caused a small, short-term elevation in maximum temperature compared to pretreatment temperature values. Orally immunized animals, except for those vaccinated with the Delta cya Delta crp pmi-3834 vpl+ strain or SC-54, developed significant serum antibody responses 21 days postvaccination as measured by enzyme-linked immunosorbent assay. No cell-mediated immune responses to heat-killed S. choleraesuis were noted at the same time point as measured with heat-killed bacteria as antigen in a lymphocyte proliferation assay. In an oral challenge exposure model with a highly virulent heterologous strain of S. choleraesuis, the Delta cya Delta crp strains with deletions in pmi were not protective. As measured by morbidity scores, the responses to challenge of the pigs vaccinated with the other four Delta cya Delta crp derivatives were significantly better than those of the nonvaccinated, challenged group. With the exception of temperature elevation and slight differences in diarrhea scores postchallenge, none of these strains differed significantly from each other in the other clinical parameters analyzed. While the commercial vaccine was protective by most of the parameters measured, it was not fully protective against challenge with virulent S. choleraesuis as judged by diarrhea scores and temperature elevation. Collectively, these data demonstrate that Delta cya Delta crp derivatives, with or without the virulence plasmid but not with deletions in the pmi gene, are candidates for vaccines for protection against salmonellosis in pigs.


* Corresponding author. Mailing address: Animal Health Discovery Research, Veterinary Infectious Diseases Section, Pharmacia & Upjohn, Inc., 7923-190-289, 7000 Portage Rd., Kalamazoo, MI 49001. Phone: (616) 833-2706. Fax: (616) 833-2769. E-mail: Michael.J.Kennedy{at}am.pnu.com.

dagger Present address: Central Research Division, Pfizer Inc., Groton, CT 06340.


Infection and Immunity, September 1999, p. 4628-4636, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 1999 by the American Society for Microbiology. All rights reserved.